{"type":"rich","version":"1.0","provider_name":"Transistor","provider_url":"https://transistor.fm","author_name":"Talking Biotech with Dr. Kevin Folta","title":"A Non-Profit Biotech Model; Therapies for Rare Diseases - Dr. Ashley Winslow","html":"<iframe width=\"100%\" height=\"180\" frameborder=\"no\" scrolling=\"no\" seamless src=\"https://share.transistor.fm/e/8236f127\"></iframe>","width":"100%","height":180,"duration":2832,"description":"This episode has two parts. The first part discusses how Odylia Therapeutics is addressing rare disease, using a novel non-profit model. The second half address two rare genetic eye diseases and the approaches being designed to address them. Dr. Ashley Winslow, CEO/CSO of Odylia, describes how a non-profit is well suited to address these rare diseases, using strategies that leverage capacities in rare disease patient communities coupled to their expertise in drug discovery.  ","thumbnail_url":"https://img.transistorcdn.com/EFQPRMJfMphAaQcxzRzhsNHuwlpkADCznXm-32y-ENA/rs:fill:0:0:1/w:400/h:400/q:60/mb:500000/aHR0cHM6Ly9pbWct/dXBsb2FkLXByb2R1/Y3Rpb24udHJhbnNp/c3Rvci5mbS9zaG93/LzI4MTE2LzE2NDQw/ODk3ODktYXJ0d29y/ay5qcGc.webp","thumbnail_width":300,"thumbnail_height":300}